(±)-Iroxanadine
(±)-Iroxanadine (BRX 005; BRX 235), a vasculoprotector, is a p38 kinase and HSP protein activator. (±)-Iroxanadine has the potential for atherosclerosis and vascular diseases research.
For research use only. We do not sell to patients.
- CAS No.: 203805-20-3
- Formula: C14H20N4O
- Molecular Weight:260.33
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
In Vitro
(±)-Iroxanadine (BRX 235; 0.1 µM; 14-24 h) has cytoprotective properties in ECs[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Vascular endothelial cells (ECs)
-
Concentration:0.1 µM
-
Incubation Time:14 h, 24 h
-
Result:Showed cytoprotective properties.
Chemical Information
-
CAS No. 203805-20-3
-
Molecular Weight 260.33
-
Formula C14H20N4O
-
SMILES
C1(C2=CC=CN=C2)=NOCC(CN3CCCCC3)N1
-
Synonyms
BRX 005; BRX 235
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
(±)-Iroxanadine Related Classifications
HY-19399A Related Classifications
Powered by Bioz